WARNING! Don't Make Another Trade Until You Read This!
Integrated biosci research, consultant
Seeking Alpha Analyst Since 2013
As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading.
Since inception, our flagship portfolio has delivered over 31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains.
Check out some of our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook.
In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis. The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.
Follow us for the latest research. And, take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!
Check out Dr. Harvey’s LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out Integrated BioSci Investing!
If you haven't gained mega-profits trading stocks, consider changing your investing/trading strategy.
Let's say, you're a day trader. Have you ever considered trying longer-term investing to complement your trades? Like a hybrid strategy.
If Warren Buffett and other gurus don't trade often, don't you think they have a good reason?
Sure you can make some money in trading. But there are other more lucrative ways of trading/investing to complement your current trading.
I get it. My message goes against conventional wisdom. So it's not for most people. It's for the bold and brave biotech investors.
And if you don't want to read it, you won't offend me if you close my article. But don't shoot the messenger. Give yourself a chance to hear my message.
If you can't wait for years, that's fine. At the very least, you should consider trying "power trades!
Here's an example of how long-term investing and power trading can help you capture additional profits:
Source: Yahoo Finance, adapted by Integrated BioSci Investing
As you can see, TGTX popped over 35.2% today.
In the past 52-weeks, TGTX gained +328.1% for IBI members who hold it for the long-term.
Though we are a long-term investing community, IBI also has a good number of traders.
Among our traders, many are keeping a separate portion of their portfolio to invest for the long haul.
Using power trades, they leverage my forecasting of clinical trial data/FDA approval to give them an edge over the market.
That's what helped a notable IBI member, tjrippe to capture that 35% gains in TG Therapeutics (TGTX). Here's his own words:
Now in day trading, you'd jump in and out of a stock in the day. You'll be able to scalp profits. I get it. But since you don't keep TGTX overnight, you'd missed out on the 35% gains today.
You might think reading the charts is your ultimate advantage. It helps to some extent. But overanalysis of the chart keeps you too busy.
The chart is good at showing you historical events. And you can capture some profits when the past repeats itself. But it's the forward-looking or the future that makes you huge gains. Why not try both?
If the charts are all there is to trading/investing, purely chartists would already be filthy rich. The reality is that the richest people in the market are long-term investors. And many investors also do some trading on the side.
You know who they are: Buffett, Lynch, Templeton, Fisher, etc.
If you believe you deserve it, my forecasting can help you'd bank over 35% profits in TGTX today.
Better yet, if you hold it for a year like Like tjrippe, you'd gain over 3 folds on your money.
If you bought $200,000 of TGTX, you'd turn it in +$600,000 in a year. That's enough to give you a Roll Royce Cullinan!
In 2021, prove to your boss/enemies you deserve more. It's time for a change. Doing the same thing will lead to the same results.
Same thing for long-term investors. If you have not been patient enough or diversified enough to catch big winners like TGTX, it's time to upgrade.
Work with me more closely. Get out of your comfort zone. Overcome your FEAR.
If you have any questions about an upcoming data release, let me know inside IBI.
As I wrote, biotech investing without forecasting is like driving in the road blindfolded. You'll be hit by a negative data release, etc.
With near prescient forecasting, you'll be able to spot out lucrative opportunities like TGTX and many other winners.
On that note, I will add more data to my forecasting track record on the 65% (i.e., more than favorable) chance category.
In the figure below, you can see that in 22 forecasts (with 65% odds), I hit the 100% accuracy rate. The TGTX accuracy will make it 23 shots 23 bullseyes.
As you can see, I do a lot of stock research and recommendations inside IBI. And I help you become the newer and better you. Some of our big winners include CRISPR Therapeutics (CRSP), CryoPort (CYRX), Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM), Corium International (CORI), Kite Pharma(KITE), Juno Therapeutics (JUNO), Sparks Therapeutics (ONCE), Tesaro(TSRO), Mirati Therapeutics (MRTX), etc ...
At IBI: Everyone is getting smarter. Everyone is respected. You don't feel like a fool. And you’re a part of something bigger than yourself.
Inside IBI, we stay ahead of the market.
I'm so confident in the value of my service that I'm giving you a 2-week FREE trial, money-back guarantee.
GET YOUR FREE GIFT TO PROFITABILITY NOW!
Analyst's Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstance are individualized.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.